Regulation note: GLP-1 medicines are registered prescription products. Investigational peptides marketed for weight loss are a separate, unapproved category — labels alone do not make supply lawful.
Triple-agonist (investigational)
An investigational metabolic peptide in clinical trials.
Read entryGrowth-hormone fragment
A fragment of growth hormone historically investigated in metabolic contexts.
Read entryGLP-1 receptor agonist
A GLP-1 receptor agonist registered for type 2 diabetes and chronic weight management.
Read entryDual GIP/GLP-1 agonist
A dual GIP/GLP-1 receptor agonist used in metabolic and weight management contexts.
Read entryGLP-1 receptor agonist
An earlier-generation GLP-1 receptor agonist used in diabetes and weight-management contexts.
Read entryInvestigational metabolic peptide (FTPP)
An investigational peptide discussed in metabolic and weight contexts.
Read entryGLP-1 receptor agonist
A once-weekly GLP-1 receptor agonist used in type 2 diabetes.
Read entryGLP-1 receptor agonist
An earlier-generation GLP-1 receptor agonist used in type 2 diabetes.
Read entryAmylin analogue (investigational)
A long-acting amylin analogue studied for weight management, often alongside semaglutide (as “CagriSema”).
Read entryGLP-1 / glucagon dual agonist (investigational)
An investigational dual GLP-1/glucagon receptor agonist studied for weight management and liver disease.
Read entryGLP-1 / glucagon dual agonist (investigational)
An investigational dual GLP-1/glucagon receptor agonist studied for weight management.
Read entryGrowth-hormone fragment
A fragment of growth hormone marketed for fat loss; closely related to AOD-9604.
Read entryThis is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.